Low nanosilica addition proved more effective in improving mechanical properties compared to higher additions. Furthermore, handling properties are unaffected by nanosilica addition.

A statistically significant difference between clinical and histopathological diagnosis has been found. The histopathological findings strongly suggest the necessity of complete curettage of lesions sizing >20 mm in order to prevent recurrences.

BACKGROUND: The serious nature of potentially malignant oral lesions (PMOL) demands that the final diagnosis be made on both clinical and histopathologic grounds. The aim of the present study was to determine the correlation between clinical and histopathologic diagnoses of PMOL using a discrepancy index (DI). METHODS: Fifty-one patients with PMOL were examined clinically, and a biopsy was taken from each one. The results of histopathologic diagnosis were compared with the clinical diagnosis. We established that the histopathologic diagnosis was incompatible when the clinical diagnosis was not confirmed. On the basis of the incompatible diagnosis, we calculated a discrepancy index between the clinical and histopathologic diagnosis. RESULTS: Clinically, the homogeneous leukoplakia was the most frequent lesion followed by erosive lichen planus and reticular lichen planus. No cases of erythroplakia were observed. Lesions were most frequently seen at the buccal mucosa, followed by the gingiva (alveolar mucosa) and tongue. The histopathologic diagnosis showed that the majority of the lesions were benign keratoses followed by lichen planus. Three cases of epithelial dysplasia were mild. The DI between clinical and histopathologic diagnosis was 17.6 %. The higher DI was found in erosive lichen planus. CONCLUSION: The obtained findings show that in 90% of leukoplakias, clinical diagnosis was confirmed by histopathologic examination. The discrepancy between clinical and histopathologic diagnoses in 17.6 % of cases suggests that all PMOLs should be submitted to histological analysis

Background/Aim. There is limited published evidence on the cytotoxicity of 3D printed polymer materials for dentistry applications, despite that they are now being widely used in medicine. Stereolithography (SLA) is one of the foremost 3D processes used in 3D printing, yet there are only a small number of resin materials reported to be suitable for medical applications. The aim of this study was to investigate, in vitro, the cytotoxic effect of the 3D printed resin in order to establish the suitability for its usage in dentistry and related medical applications such as surgical dental guides, occlusal splits and orthodontic devices. Methods. To examine the cytotoxicity of the 3D printed polymer-based epoxy resin, Accura? ClearVue? (3D-Systems, USA), two cell cultures were used: mouse fibroblasts L929 and human lung fibroblasts MRC-5. Cell viability was determined by Mosmann's colorimetric (MTT) test and the agar diffusion test (ADT). Results. Direct contact of the tested material with ADT test showed nontoxic effects of tested material in any cell culture. The tested material showed no cytotoxic effect after 3 days of extraction of the eluate by MTT test, but mild cytotoxic effect after 5, 7 and 21 days on both cell lines. The cytotoxicity increased with increasing the time of the eluate extraction. Conclusion. 3D printed polymer-based epoxy resin, Accura? ClearVue? (3D-Systems, USA) is considered appropriate for making surgical dental implant guides according to the cytotoxic behavior. According to the mild level of cytotoxicity after the longer extraction periods, there is a need for further evaluation of biocompatibility for its application for occlusal splints and orthodontic devices. [Project of the Serbian Ministry of Education, Science and Technological Development, Grant no. TR 35020: Research and development of modeling methods and approaches in manufacturing of dental recoveries with the application of modern technologies and computer aided systems]

Application of 3D CBCT images, computer-aided systems and software in manufacturing custom bone grafts represents the most recent method of guided bone regeneration. This method substantially reduces time of recovery and carries minimum risk of postoperative complications, yet the results fully satisfy the requirements of both the patient and the therapist.